Upgrade to SI Premium - Free Trial

Johnson & Johnson (JNJ) PT Lowered to $115 at Goldman Sachs, Says Response On Drug Prices Was Underwhelming

January 25, 2017 3:14 AM
Goldman Sachs lowered its price target on Johnson & Johnson (NYSE: JNJ) to $115.00 (from $120.00) while maintaining a Neutral ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst PT Change Hot Comments

Next Articles